Bayesian Capital Management’s Zomedica Corp. ZOM Stock Holding History

Bayesian Capital Management’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,000	Closed	-$7K	–	564
2021 Q3	$7K	Sell	13,000 -30,200	-70%	-$17.8K	﹤0.01%	362
2021 Q2	$36K	Buy	+43,200	New	+$40.3K	0.01%	387

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

PWMG

Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return

Bayesian Capital Management's ZOM Position: Q4 2021 in Review

Bayesian Capital Management sold out of Zomedica Corp. (ZOM) in Q4 2021, closing a stake of 13,000 shares — an estimated $7K sold.

Bayesian Capital Management first reported a position in ZOM in Q2 2021 and held it in 2 quarters. The position peaked at $36K in Q2 2021. 107 funds tracked by Wall St. Rank hold ZOM as of Q4 2021.

Bayesian Capital Management reported no remaining Zomedica Corp. position as of Q4 2021 after selling out during the quarter.
Bayesian Capital Management sold 13,000 Zomedica Corp. shares in Q4 2021, an estimated $7K.
Bayesian Capital Management first reported a position in Zomedica Corp. in Q2 2021 and held it in 2 quarters.
Bayesian Capital Management's Zomedica Corp. position peaked at $36K in Q2 2021.
107 funds tracked by Wall St. Rank held Zomedica Corp. as of Q4 2021.

Based on Bayesian Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.